Retirement Systems of Alabama Sells 525 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Retirement Systems of Alabama cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,611 shares of the biopharmaceutical company’s stock after selling 525 shares during the quarter. Retirement Systems of Alabama’s holdings in Regeneron Pharmaceuticals were worth $20,737,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in REGN. FMR LLC raised its stake in Regeneron Pharmaceuticals by 7.3% in the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock valued at $8,098,661,000 after acquiring an additional 669,517 shares during the period. International Assets Investment Management LLC raised its position in shares of Regeneron Pharmaceuticals by 76,169.5% in the fourth quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock valued at $519,148,000 after purchasing an additional 590,314 shares during the period. abrdn plc lifted its stake in shares of Regeneron Pharmaceuticals by 552.8% during the 4th quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company’s stock valued at $193,136,000 after buying an additional 186,215 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in Regeneron Pharmaceuticals by 129.3% in the 4th quarter. Assenagon Asset Management S.A. now owns 216,523 shares of the biopharmaceutical company’s stock worth $190,170,000 after buying an additional 122,103 shares during the period. Finally, TD Asset Management Inc grew its stake in Regeneron Pharmaceuticals by 64.4% in the 3rd quarter. TD Asset Management Inc now owns 180,267 shares of the biopharmaceutical company’s stock valued at $148,353,000 after buying an additional 70,628 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $954.22, for a total transaction of $95,422.00. Following the transaction, the director now directly owns 18,382 shares in the company, valued at approximately $17,540,472.04. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $954.22, for a total transaction of $95,422.00. Following the completion of the sale, the director now owns 18,382 shares of the company’s stock, valued at approximately $17,540,472.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bonnie L. Bassler sold 854 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $979.25, for a total transaction of $836,279.50. Following the completion of the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,353,323.50. The disclosure for this sale can be found here. Insiders sold 10,195 shares of company stock worth $9,759,898 in the last ninety days. 8.83% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Trading Up 1.1 %

REGN stock opened at $892.48 on Tuesday. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33. The company has a market capitalization of $97.96 billion, a PE ratio of 25.68, a price-to-earnings-growth ratio of 2.54 and a beta of 0.11. The company’s 50 day moving average price is $946.89 and its two-hundred day moving average price is $894.83. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The business had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. During the same period in the previous year, the firm posted $10.96 earnings per share. The firm’s revenue for the quarter was up .6% on a year-over-year basis. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

REGN has been the topic of several recent research reports. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Royal Bank of Canada restated an “outperform” rating and issued a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. TD Cowen upped their target price on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Barclays raised their price target on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a report on Tuesday, January 23rd. Finally, Sanford C. Bernstein initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $977.77.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.